Quick Answer
Nautilus Biotechnology, Inc. reported Research And Development Expense of $41.11 million for the year ending 2025.
- Nautilus Biotechnology, Inc. showed a decrease of -18.6% in Research And Development Expense from 2024 to 2025.
- This data is from Nautilus Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $2.75 million | Q3 2020: $3.32 million | Q1 2021: $4.84 million | Q2 2021: $6.38 million | Q3 2021: $8.24 million | Q1 2022: $9.66 million | Q2 2022: $8.86 million | Q3 2022: $9.57 million | Q1 2023: $10.88 million | Q2 2023: $11.91 million | Q3 2023: $12.00 million | Q1 2024: $12.93 million | Q2 2024: $12.44 million | Q3 2024: $12.29 million | Q1 2025: $11.54 million | Q2 2025: $10.39 million | Q3 2025: $9.61 million.
- Over the full 6 years of available data (2020 to 2025), Nautilus Biotechnology, Inc.'s Research And Development Expense has grown by 230.7%.
- Historical annual values: Fiscal year 2025: $41.11 million | Fiscal year 2024: $50.48 million | Fiscal year 2023: $47.25 million | Fiscal year 2022: $37.67 million | Fiscal year 2021: $29.35 million | Fiscal year 2020: $12.43 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: